Cargando…

Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment

INTRODUCTION: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiramatsu, Takeyuki, Ito, Hiroki, Okumura, Shota, Asano, Yuko, Iguchi, Daiki, Furuta, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919219/
https://www.ncbi.nlm.nih.gov/pubmed/33371732
http://dx.doi.org/10.1177/1479164120971220
_version_ 1783658092915851264
author Hiramatsu, Takeyuki
Ito, Hiroki
Okumura, Shota
Asano, Yuko
Iguchi, Daiki
Furuta, Shinji
author_facet Hiramatsu, Takeyuki
Ito, Hiroki
Okumura, Shota
Asano, Yuko
Iguchi, Daiki
Furuta, Shinji
author_sort Hiramatsu, Takeyuki
collection PubMed
description INTRODUCTION: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 diabetes patients with renal impairment. MATERIALS AND METHODS: A total of 156 patients referred with suboptimal glycemic control were assigned to Group G (GLP-1): n = 72 or Group S (SGLT-2 inhibitor)—dapagliflozin (n = 52) or empagliflozin (n = 32). Renal function was assessed every 3 months for 36 months. Cardiovascular parameters were evaluated every 12 months for 36 months. RESULTS: Compared with baseline, HbA1c and systolic blood pressure significantly decreased in both groups (p < 0.05). The estimated glomerular filtration rate decreased, but without significance. Albuminuria decreased significantly in both groups and then subsequently increased after 30 months in Group S. Diastolic cardiac function, assessed by E/e′ or left atrial volume index, decreased only in Group G at 36 months. CONCLUSIONS: The GLP-1 receptor agonist and SGLT-2 inhibitors were effective for glycemic and blood pressure control and for maintaining renal function. The GLP-1 receptor agonist improved diastolic function at 36 months.
format Online
Article
Text
id pubmed-7919219
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-79192192021-03-02 Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment Hiramatsu, Takeyuki Ito, Hiroki Okumura, Shota Asano, Yuko Iguchi, Daiki Furuta, Shinji Diab Vasc Dis Res Original Article INTRODUCTION: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 diabetes patients with renal impairment. MATERIALS AND METHODS: A total of 156 patients referred with suboptimal glycemic control were assigned to Group G (GLP-1): n = 72 or Group S (SGLT-2 inhibitor)—dapagliflozin (n = 52) or empagliflozin (n = 32). Renal function was assessed every 3 months for 36 months. Cardiovascular parameters were evaluated every 12 months for 36 months. RESULTS: Compared with baseline, HbA1c and systolic blood pressure significantly decreased in both groups (p < 0.05). The estimated glomerular filtration rate decreased, but without significance. Albuminuria decreased significantly in both groups and then subsequently increased after 30 months in Group S. Diastolic cardiac function, assessed by E/e′ or left atrial volume index, decreased only in Group G at 36 months. CONCLUSIONS: The GLP-1 receptor agonist and SGLT-2 inhibitors were effective for glycemic and blood pressure control and for maintaining renal function. The GLP-1 receptor agonist improved diastolic function at 36 months. SAGE Publications 2020-12-29 /pmc/articles/PMC7919219/ /pubmed/33371732 http://dx.doi.org/10.1177/1479164120971220 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Hiramatsu, Takeyuki
Ito, Hiroki
Okumura, Shota
Asano, Yuko
Iguchi, Daiki
Furuta, Shinji
Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
title Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
title_full Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
title_fullStr Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
title_full_unstemmed Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
title_short Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
title_sort impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919219/
https://www.ncbi.nlm.nih.gov/pubmed/33371732
http://dx.doi.org/10.1177/1479164120971220
work_keys_str_mv AT hiramatsutakeyuki impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment
AT itohiroki impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment
AT okumurashota impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment
AT asanoyuko impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment
AT iguchidaiki impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment
AT furutashinji impactofglucagonlikepeptide1receptoragonistandsodiumglucosecotransporter2inhibitorsontype2diabetespatientswithrenalimpairment